FR901228A
(fr)
|
1943-01-16 |
1945-07-20 |
Deutsche Edelstahlwerke Ag |
Système d'aimant à entrefer annulaire
|
US2940972A
(en)
|
1957-06-27 |
1960-06-14 |
Thomae Gmbh Dr K |
Tri-and tetra-substituted pteridine derivatives
|
US4666828A
(en)
|
1984-08-15 |
1987-05-19 |
The General Hospital Corporation |
Test for Huntington's disease
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
US4801531A
(en)
|
1985-04-17 |
1989-01-31 |
Biotechnology Research Partners, Ltd. |
Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
|
US5272057A
(en)
|
1988-10-14 |
1993-12-21 |
Georgetown University |
Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
|
US5192659A
(en)
|
1989-08-25 |
1993-03-09 |
Genetype Ag |
Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
|
US5710158A
(en)
|
1991-05-10 |
1998-01-20 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
GB9125001D0
(en)
|
1991-11-25 |
1992-01-22 |
Ici Plc |
Heterocyclic compounds
|
GB9300059D0
(en)
|
1992-01-20 |
1993-03-03 |
Zeneca Ltd |
Quinazoline derivatives
|
AU6909194A
(en)
|
1993-05-14 |
1994-12-12 |
Board Of Regents, The University Of Texas System |
Preparation of n-cyanodithioimino-carbonates and 3-mercapto-5-amino-1h-1,2,4-triazole
|
US5700823A
(en)
|
1994-01-07 |
1997-12-23 |
Sugen, Inc. |
Treatment of platelet derived growth factor related disorders such as cancers
|
IL115256A0
(en)
|
1994-11-14 |
1995-12-31 |
Warner Lambert Co |
6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
|
US6331555B1
(en)
|
1995-06-01 |
2001-12-18 |
University Of California |
Treatment of platelet derived growth factor related disorders such as cancers
|
CA2262403C
(fr)
|
1995-07-31 |
2011-09-20 |
Urocor, Inc. |
Biomarqueurs et cibles de diagnostic, de pronostic et de traitement du cancer de la prostate
|
US6218529B1
(en)
|
1995-07-31 |
2001-04-17 |
Urocor, Inc. |
Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
|
JP4130700B2
(ja)
|
1996-02-26 |
2008-08-06 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
抗腫瘍剤含有組成物
|
TW472045B
(en)
|
1996-09-25 |
2002-01-11 |
Astra Ab |
Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
|
SK286084B6
(sk)
|
1997-05-28 |
2008-03-05 |
Aventis Pharmaceuticals Inc. |
Derivát chinoxalínu, farmaceutický prostriedok obsahujúci tento derivát a použitie
|
US6235740B1
(en)
|
1997-08-25 |
2001-05-22 |
Bristol-Myers Squibb Co. |
Imidazoquinoxaline protein tyrosine kinase inhibitors
|
UA71555C2
(en)
|
1997-10-06 |
2004-12-15 |
Zentaris Gmbh |
Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
|
WO1999042461A1
(fr)
|
1998-02-23 |
1999-08-26 |
Warner-Lambert Company |
Derives de quinoxaline substitues utilises comme antagonistes du recepteur de l'interleukine-8
|
JP2002534512A
(ja)
|
1999-01-15 |
2002-10-15 |
ノボ ノルディスク アクティーゼルスカブ |
非ペプチドglp−1アゴニスト
|
CA2372990C
(fr)
|
1999-05-05 |
2007-06-19 |
Institut Curie |
Moyens de detection et de traitement des pathologies associees au fgfr3
|
US7135311B1
(en)
|
1999-05-05 |
2006-11-14 |
Institut Curie |
Means for detecting and treating pathologies linked to FGFR3
|
CZ2002846A3
(cs)
|
1999-09-15 |
2003-02-12 |
Warner-Lambert Company |
Pteridinony, jako inhibitory kinasy
|
DE10013318A1
(de)
|
2000-03-17 |
2001-09-20 |
Merck Patent Gmbh |
Formulierung enthaltend Chinoxalinderivate
|
WO2002076985A1
(fr)
|
2001-03-23 |
2002-10-03 |
Smithkline Beecham Corporation |
Composes utiles en tant qu'inhibiteurs de kinases pour le traitement des maladies hyperproliferatives
|
US20030235628A1
(en)
|
2001-09-19 |
2003-12-25 |
Rajneesh Taneja |
Methods and pharmaceutical formulations for protecting pharmaceutical compounds from acidic environments
|
EP1458383B1
(fr)
|
2001-12-18 |
2007-11-21 |
Merck & Co., Inc. |
Modulateurs pyrazole a substitution heteroaryle du recepteur 5 metabotropique de glutamate
|
CN101973998A
(zh)
|
2001-12-20 |
2011-02-16 |
Osi药物公司 |
吡咯并嘧啶A2b选择性拮抗剂化合物
|
PT1463506E
(pt)
|
2001-12-24 |
2009-12-10 |
Astrazeneca Ab |
Derivados de quinazolina substituídos como inibidores de aurora cinases
|
JP2003213463A
(ja)
|
2002-01-17 |
2003-07-30 |
Sumitomo Chem Co Ltd |
金属腐食防止剤および洗浄液
|
AU2003223467B2
(en)
|
2002-04-08 |
2007-10-04 |
Merck Sharp & Dohme Corp. |
Inhibitors of Akt activity
|
US20040097725A1
(en)
|
2002-07-10 |
2004-05-20 |
Norman Herron |
Charge transport compositions and electronic devices made with such compositions
|
PA8577501A1
(es)
|
2002-07-25 |
2004-02-07 |
Warner Lambert Co |
Inhibidores de quinasas
|
US7825132B2
(en)
|
2002-08-23 |
2010-11-02 |
Novartis Vaccines And Diagnostics, Inc. |
Inhibition of FGFR3 and treatment of multiple myeloma
|
KR20110050745A
(ko)
|
2002-10-03 |
2011-05-16 |
탈자진 인코포레이티드 |
혈관항상성 유지제 및 그의 사용 방법
|
WO2004037293A1
(fr)
|
2002-10-22 |
2004-05-06 |
Dainippon Pharmaceutical Co., Ltd. |
Composition stabilisee
|
AR043059A1
(es)
|
2002-11-12 |
2005-07-13 |
Bayer Pharmaceuticals Corp |
Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiper-proliferativos
|
US7098332B2
(en)
|
2002-12-20 |
2006-08-29 |
Hoffmann-La Roche Inc. |
5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
|
ATE433967T1
(de)
|
2003-01-17 |
2009-07-15 |
Warner Lambert Co |
2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
|
US20040204450A1
(en)
|
2003-03-28 |
2004-10-14 |
Pfizer Inc |
Quinoline and quinoxaline compounds
|
WO2004098494A2
(fr)
|
2003-04-30 |
2004-11-18 |
Cytokinetics, Inc. |
Composés, compositions et procédés
|
CN102584813B
(zh)
|
2003-05-14 |
2016-07-06 |
Ngc药物公司 |
化合物及其在调节淀粉样蛋白β中的用途
|
JP4571944B2
(ja)
|
2003-05-23 |
2010-10-27 |
エテルナ ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング |
新規のピリドピラジン及びそれらのキナーゼモジュレーターとしての使用
|
DE10323345A1
(de)
|
2003-05-23 |
2004-12-16 |
Zentaris Gmbh |
Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
|
WO2005007099A2
(fr)
|
2003-07-10 |
2005-01-27 |
Imclone Systems Incorporated |
Inhibiteurs de la pkb utilises comme agents antitumoraux
|
CA2533417A1
(fr)
|
2003-07-21 |
2005-02-03 |
Mitchell A. Avery |
Conception et synthese de ligands optimise pour ppar
|
CN1829709A
(zh)
|
2003-08-01 |
2006-09-06 |
健亚生物科技公司 |
对抗黄病毒的双环咪唑衍生物
|
CA2537224A1
(fr)
|
2003-10-17 |
2005-05-06 |
4 Aza Bioscience Nv |
Derives de pteridine substitues par des heterocycles et leur utilisation a des fins therapeutiques
|
WO2005041940A1
(fr)
|
2003-10-30 |
2005-05-12 |
Lupin Ltd. |
Formulations stables d'inhibiteurs d'ace, et methodes de preparation desdites formulations
|
AU2004288709B2
(en)
|
2003-11-07 |
2011-01-06 |
Novartis Vaccines And Diagnostics, Inc. |
Methods for synthesizing quinolinone compounds
|
WO2005054201A1
(fr)
|
2003-11-20 |
2005-06-16 |
Janssen Pharmaceutica N.V. |
2-quinolinones et 2-quinoxalinones substituees par 6-alcenyle et 6-phenylalkyle utilisees comme inhibiteurs de la poly(adp-ribose) polymerase (parp)
|
KR100861515B1
(ko)
|
2003-11-24 |
2008-10-02 |
에프. 호프만-라 로슈 아게 |
피라졸릴 및 이미다졸릴 피리미딘
|
KR101164258B1
(ko)
|
2003-12-23 |
2012-07-11 |
아스텍스 테라퓨틱스 리미티드 |
단백질 키나아제 조절제로서의 피라졸 유도체
|
US7098222B2
(en)
|
2004-05-12 |
2006-08-29 |
Abbott Laboratories |
Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
|
US7205316B2
(en)
|
2004-05-12 |
2007-04-17 |
Abbott Laboratories |
Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands
|
US7446196B2
(en)
|
2004-06-03 |
2008-11-04 |
Kosan Biosciences, Incorporated |
Leptomycin compounds
|
WO2006024834A1
(fr)
|
2004-08-31 |
2006-03-09 |
Astrazeneca Ab |
Dérivés de quinazolinone et utilisation de ces dérivés en tant qu'inhibiteurs du b-raf
|
US7268231B2
(en)
|
2004-10-14 |
2007-09-11 |
Hoffmann-La Roche Inc. |
1,5-Naphthyridine azolinone
|
EP1828147A1
(fr)
|
2004-10-15 |
2007-09-05 |
AstraZeneca AB |
Quinoxalines en tant qu'inhibiteurs b-raf
|
EP1659175A1
(fr)
|
2004-11-18 |
2006-05-24 |
Institut Curie |
Altérations des kératoses séborrhéiques et applications dérivées
|
CA2589993C
(fr)
|
2004-12-09 |
2012-07-03 |
Insys Therapeutics, Inc. |
Formulations de dronabinol stable a temperature de laboratoire
|
EP2650010A1
(fr)
|
2004-12-24 |
2013-10-16 |
Spinifex Pharmaceuticals Pty Ltd |
Procédé de traitement de la prophylaxie
|
WO2006085335A2
(fr)
|
2005-01-03 |
2006-08-17 |
Lupin Limited |
Composition pharmaceutique de substances labiles acides
|
JP2008530030A
(ja)
|
2005-02-14 |
2008-08-07 |
バイオノミックス リミテッド |
新規なチューブリン重合阻害剤
|
US9271963B2
(en)
|
2005-03-03 |
2016-03-01 |
Universitat Des Saarlandes |
Selective inhibitors of human corticosteroid synthases
|
US20090156617A1
(en)
|
2005-05-12 |
2009-06-18 |
Northrup Alan B |
Tyrosine kinase inhibitors
|
DK1901729T3
(da)
|
2005-05-13 |
2012-05-14 |
Topotarget Uk Ltd |
Farmaceutiske formuleringer af HDAC-inhibitorer
|
MX2007014258A
(es)
|
2005-05-18 |
2008-01-22 |
Wyeth Corp |
Inhibidores de 4,6-diamino-[1,7]naftiridin-3-carbonitrilo de la tpl2 cinasa y metodos de fabricacion y uso de los mismos.
|
US8945543B2
(en)
|
2005-06-10 |
2015-02-03 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilizer for protein preparation comprising meglumine and use thereof
|
GB0513692D0
(en)
|
2005-07-04 |
2005-08-10 |
Karobio Ab |
Novel pharmaceutical compositions
|
CA2618479C
(fr)
|
2005-08-26 |
2014-12-30 |
Laboratoires Serono S.A. |
Derive de pyrazine et leur utilisation en tant qu'inhibiteurs de pi3k
|
CN103819416A
(zh)
|
2005-10-07 |
2014-05-28 |
埃克塞里艾克西斯公司 |
N-(3-氨基-喹喔啉-2-基)-磺酰胺衍生物及其作为磷脂酰肌醇3-激酶抑制剂的用途
|
JP5527972B2
(ja)
|
2005-11-11 |
2014-06-25 |
エテルナ ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング |
新規のピリドピラジン及び前記ピリドピラジンをキナーゼのモジュレーターとして用いる使用
|
US8217042B2
(en)
|
2005-11-11 |
2012-07-10 |
Zentaris Gmbh |
Pyridopyrazines and their use as modulators of kinases
|
EP1790342A1
(fr)
|
2005-11-11 |
2007-05-30 |
Zentaris GmbH |
Dérivés de pyridopyrazine et leur utilisation comme modulateurs de transduction de signal
|
CN1966500B
(zh)
|
2005-11-17 |
2011-03-30 |
中国科学院上海药物研究所 |
一类喹喔啉类衍生物、制法及用途
|
WO2007061130A1
(fr)
|
2005-11-22 |
2007-05-31 |
Eisai R & D Management Co., Ltd. |
Agent antitumeur pour myelomes multiples
|
NZ568807A
(en)
*
|
2005-12-21 |
2011-05-27 |
Janssen Pharmaceutica Nv |
Triazolopyridazines as tyrosine kinase modulators
|
AR060358A1
(es)
|
2006-04-06 |
2008-06-11 |
Novartis Vaccines & Diagnostic |
Quinazolinas para la inhibicion de pdk 1
|
WO2007125405A2
(fr)
|
2006-05-01 |
2007-11-08 |
Pfizer Products Inc. |
Composés hétérocycliques 2-amino-substitués à cycles fusionnés
|
GB0609621D0
(en)
|
2006-05-16 |
2006-06-21 |
Astrazeneca Ab |
Novel co-crystal
|
EP2029600B1
(fr)
|
2006-05-24 |
2012-03-14 |
Boehringer Ingelheim International GmbH |
Ptéridines substituées par un hétérocycle à quatre chaînons
|
TWI398252B
(zh)
|
2006-05-26 |
2013-06-11 |
Novartis Ag |
吡咯并嘧啶化合物及其用途
|
CA2657702A1
(fr)
|
2006-07-03 |
2008-01-10 |
Vereniging Voor Christelijk Hoger Onderwijs Wetenschappelijk Onderzoek E N Patieentenzorg |
Quinazolines et composes heterocycliques apparentes et utilisation therapeutique connexe
|
JP2010500994A
(ja)
|
2006-08-16 |
2010-01-14 |
エグゼリクシス, インコーポレイテッド |
Pi3kおよびmekモジュレーターを使用する方法
|
US8148361B2
(en)
|
2006-11-10 |
2012-04-03 |
Bristol-Myers Squibb Company |
Kinase inhibitors
|
JP2008127446A
(ja)
|
2006-11-20 |
2008-06-05 |
Canon Inc |
1,5−ナフチリジン化合物及び有機発光素子
|
KR101588583B1
(ko)
|
2006-11-22 |
2016-01-28 |
인사이트 코포레이션 |
키나제 억제제로서의 이미다조트리아진 및 이미다조피리미딘
|
CN102123712B
(zh)
|
2006-12-13 |
2014-03-19 |
默沙东公司 |
使用igf1r抑制剂治疗癌症的方法
|
US7872018B2
(en)
|
2006-12-21 |
2011-01-18 |
Plexxikon, Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
EA200900819A1
(ru)
|
2006-12-22 |
2010-02-26 |
Новартис Аг |
Хиназолины для ингибирования pdk1
|
EP2114941B1
(fr)
|
2006-12-22 |
2015-03-25 |
Astex Therapeutics Limited |
Composés hétérocycliques bicycliques servant d'inhibiteurs des fgfr
|
KR20080062876A
(ko)
|
2006-12-29 |
2008-07-03 |
주식회사 대웅제약 |
신규한 항진균성 트리아졸 유도체
|
WO2008109369A2
(fr)
|
2007-03-02 |
2008-09-12 |
Mdrna, Inc. |
Composés d'acide nucléique permettant d'inhiber l'expression de gène tnf et utilisations de ceux-ci
|
US8163923B2
(en)
|
2007-03-14 |
2012-04-24 |
Advenchen Laboratories, Llc |
Spiro substituted compounds as angiogenesis inhibitors
|
CL2008001356A1
(es)
|
2007-05-10 |
2008-11-14 |
Smithkline Beecham Corp |
Compuestos derivados de quinoxalina, inhibidores de la pi3 quinasa _(p13ka, pi3ko, pi3b y/o pi3ky); composicion farmaceutica; uso para tratar un trastorno autoinmune, enfermedad inflamatoria, cardiovascular, neurodegerativa, alergia, asma, enfermedad renal, cancer, rechazo de transplante, lesiones pulmonares.
|
EP1990342A1
(fr)
|
2007-05-10 |
2008-11-12 |
AEterna Zentaris GmbH |
Dérivés de pyridopyrazine, processus de fabrication et utilisations correspondantes
|
JP2010529031A
(ja)
|
2007-05-29 |
2010-08-26 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
Pi3キナーゼ阻害剤としてのナフチリジン誘導体
|
AR066879A1
(es)
|
2007-06-08 |
2009-09-16 |
Novartis Ag |
Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
|
PT2172450E
(pt)
|
2007-06-20 |
2013-10-28 |
Mitsubishi Tanabe Pharma Corp |
Novo derivado sulfonamida de ácido malónico e sua utilização farmacêutica
|
JP5548123B2
(ja)
*
|
2007-06-21 |
2014-07-16 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
6−{ジフルオロ[6−(1−メチル−1H−ピラゾル−4−イル)[1,2,4]トリアゾロ[4,3−b]ピリダジン−3−イル]メチル}キノリンの多形および水和物の形態、塩、ならびに製造方法
|
EP2173338A1
(fr)
|
2007-07-06 |
2010-04-14 |
OSI Pharmaceuticals, Inc. |
Traitement anticancéreux en combinaison
|
WO2009020990A1
(fr)
|
2007-08-08 |
2009-02-12 |
Smithkline Beecham Corporation |
Dérivés de 2-[(2-{phénylamino}-1h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]benzamide en tant qu'inhibiteur d'igf-1r pour le traitement du cancer
|
WO2009019518A1
(fr)
|
2007-08-09 |
2009-02-12 |
Astrazeneca Ab |
Composés de pyrimidine ayant un effet inhibiteur du fgfr
|
EP2173354A4
(fr)
|
2007-08-09 |
2011-10-05 |
Glaxosmithkline Llc |
Dérivés des quinoxalines utilisés comme inhibiteurs des pi3-kinases
|
WO2013173485A1
(fr)
|
2012-05-15 |
2013-11-21 |
Predictive Biosciences, Inc. |
Détection de cancers de la vessie
|
US20090054304A1
(en)
|
2007-08-23 |
2009-02-26 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
EA020777B1
(ru)
|
2007-11-16 |
2015-01-30 |
Инсайт Корпорейшн |
4-пиразолил-n-арилпиримидин-2-амины, 4-пиразолил-n-пиразолилпиримидин-2-амины и 4-пиразолил-n-пиридилпиримидин-2-амины в качестве ингибиторов киназ janus
|
SI2234600T1
(sl)
|
2007-12-21 |
2014-12-31 |
F. Hoffmann-La Roche Ag |
Farmacevtska oblika protitelesa
|
EP2282739A2
(fr)
|
2008-05-05 |
2011-02-16 |
Schering Corporation |
Administration séquentielle d agents de chimiothérapie pour le traitement du cancer
|
CN102036963B
(zh)
|
2008-05-23 |
2013-08-21 |
诺瓦提斯公司 |
作为蛋白酪氨酸激酶抑制剂的喹啉类和喹喔啉类衍生物
|
WO2010056872A2
(fr)
|
2008-11-15 |
2010-05-20 |
Rib-X Pharmaceuticals, Inc. |
Compositions antimicrobiennes
|
EP2356116A1
(fr)
|
2008-11-20 |
2011-08-17 |
OSI Pharmaceuticals, Inc. |
Pyrroloý2,3-b¨-pyridines et pyrroloý2,3-b¨-pyrazines substituées
|
CN102361863B
(zh)
|
2009-01-21 |
2014-12-03 |
巴斯利尔药物股份公司 |
新的二环抗生素
|
CA2750051A1
(fr)
|
2009-02-02 |
2010-08-05 |
Merck Sharp & Dohme Corp. |
Inhibiteurs de l'activite d'akt
|
TW201041888A
(en)
|
2009-05-06 |
2010-12-01 |
Plexxikon Inc |
Compounds and methods for kinase modulation, and indications therefor
|
FR2945950A1
(fr)
|
2009-05-27 |
2010-12-03 |
Elan Pharma Int Ltd |
Compositions de nanoparticules anticancereuses et procedes pour les preparer
|
AU2010258214B2
(en)
|
2009-06-12 |
2015-08-20 |
Abivax |
Compounds useful for treating premature aging and in particular progeria
|
AU2010283806A1
(en)
|
2009-08-12 |
2012-03-01 |
Novartis Ag |
Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
|
DK2473504T3
(en)
|
2009-09-03 |
2015-03-16 |
Bioenergenix |
Heterocyclic Compounds for Inhibition of Passover
|
JP5728683B2
(ja)
|
2009-09-04 |
2015-06-03 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH |
チロシンスレオニンキナーゼ阻害剤としての置換アミノキノキサリン
|
CN104739821B
(zh)
|
2009-09-18 |
2018-04-06 |
赛诺菲 |
稳定性提高的(z)‑2‑氰基‑3‑羟基‑丁‑2‑烯酸‑(4’‑三氟甲基苯基)‑酰胺片剂制剂
|
US20110123545A1
(en)
|
2009-11-24 |
2011-05-26 |
Bristol-Myers Squibb Company |
Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseases
|
EP2332939A1
(fr)
|
2009-11-26 |
2011-06-15 |
Æterna Zentaris GmbH |
Nouveaux dérivés de naphtyridine et l'utilisation associée en tant qu'inhibiteurs de kinase
|
BR112012024678A2
(pt)
|
2010-03-30 |
2016-06-07 |
Verseon Corp |
composto, composição farmacêutica, e, métodos para tratar e para previnir uma doença ou distúrbio
|
GB201007286D0
(en)
|
2010-04-30 |
2010-06-16 |
Astex Therapeutics Ltd |
New compounds
|
US8513421B2
(en)
|
2010-05-19 |
2013-08-20 |
Millennium Pharmaceuticals, Inc. |
Substituted hydroxamic acids and uses thereof
|
WO2011149937A1
(fr)
|
2010-05-24 |
2011-12-01 |
Intellikine, Inc. |
Composés hétérocycliques et leurs utilisations
|
GB201020179D0
(en)
|
2010-11-29 |
2011-01-12 |
Astex Therapeutics Ltd |
New compounds
|
CN102532141A
(zh)
*
|
2010-12-08 |
2012-07-04 |
中国科学院上海药物研究所 |
[1,2,4]***并[4,3-b][1,2,4]三嗪类化合物、其制备方法和用途
|
WO2012104776A1
(fr)
|
2011-01-31 |
2012-08-09 |
Novartis Ag |
Dérivés hétérocycliques inédits
|
WO2012106556A2
(fr)
|
2011-02-02 |
2012-08-09 |
Amgen Inc. |
Méthodes et compositions associées à l'inhibition d'igf-1r
|
CN103491962B
(zh)
|
2011-02-23 |
2016-10-12 |
因特利凯有限责任公司 |
激酶抑制剂的组合及其用途
|
WO2012118492A1
(fr)
|
2011-03-01 |
2012-09-07 |
Array Biopharma Inc. |
Sulfonamides hétérocycliques en tant qu'inhibiteurs de raf
|
US9896730B2
(en)
|
2011-04-25 |
2018-02-20 |
OSI Pharmaceuticals, LLC |
Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
|
EP2747767B8
(fr)
|
2011-08-26 |
2019-07-17 |
Neupharma, Inc. |
Entités chimiques, compositions et procédés
|
AU2012308238B2
(en)
|
2011-09-14 |
2017-05-25 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
EP2757885B1
(fr)
|
2011-09-21 |
2017-03-15 |
Neupharma, Inc. |
Entités chimiques, compositions, et procédés spécifiques
|
WO2013089882A2
(fr)
|
2011-09-27 |
2013-06-20 |
The Regents Of The University Of Michigan |
Fusions de gènes récurrentes dans le cancer du sein
|
AU2012318580A1
(en)
|
2011-10-04 |
2014-05-22 |
Gilead Calistoga Llc |
Novel quinoxaline inhibitors of PI3K
|
GB201118652D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
GB201118675D0
(en)
|
2011-10-28 |
2011-12-14 |
Astex Therapeutics Ltd |
New compounds
|
GB201118654D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
SG11201401716XA
(en)
|
2011-10-28 |
2014-05-29 |
Novartis Ag |
Novel purine derivatives and their use in the treatment of disease
|
JO3210B1
(ar)
|
2011-10-28 |
2018-03-08 |
Merck Sharp & Dohme |
مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
|
GB201118656D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
AR088941A1
(es)
|
2011-11-23 |
2014-07-16 |
Bayer Ip Gmbh |
Anticuerpos anti-fgfr2 y sus usos
|
WO2013088191A1
(fr)
|
2011-12-12 |
2013-06-20 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Antagoniste du récepteur 3 du facteur de croissance des fibroblastes (fgfr3) à utiliser dans le traitement ou la prévention de troubles squelettiques liés à une activation anormale du fgfr3
|
AU2013228389A1
(en)
|
2012-03-08 |
2014-09-25 |
Astellas Pharma Inc. |
Novel FGFR3 fusion product
|
CA2866321A1
(fr)
|
2012-04-03 |
2013-10-10 |
Novartis Ag |
Combinaisons d'inhibiteurs de tyrosine kinase et leur utilisation
|
US9254288B2
(en)
|
2012-05-07 |
2016-02-09 |
The Translational Genomics Research Institute |
Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
|
GB201209613D0
(en)
|
2012-05-30 |
2012-07-11 |
Astex Therapeutics Ltd |
New compounds
|
GB201209609D0
(en)
|
2012-05-30 |
2012-07-11 |
Astex Therapeutics Ltd |
New compounds
|
CN104619840A
(zh)
|
2012-07-05 |
2015-05-13 |
日本国立癌症研究中心 |
Fgfr2融合基因
|
MX2015000337A
(es)
|
2012-07-09 |
2015-09-25 |
Coherus Biosciences Inc |
Formulaciones de etanercept que exhiben reduccion notable en particulas subvisibles.
|
US20150203589A1
(en)
|
2012-07-24 |
2015-07-23 |
The Trustees Of Columbia University In The City Of New York |
Fusion proteins and methods thereof
|
KR102132149B1
(ko)
|
2012-07-24 |
2020-07-09 |
더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 |
융합 단백질 및 그의 방법
|
CN104487087A
(zh)
|
2012-07-27 |
2015-04-01 |
基因泰克公司 |
治疗fgfr3相关疾患的方法
|
US10689705B2
(en)
|
2012-09-27 |
2020-06-23 |
Chugai Seiyaku Kabushiki Kaisha |
FGFR3 fusion gene and pharmaceutical drug targeting same
|
CA2890346A1
(fr)
|
2012-11-05 |
2014-05-08 |
Foundation Medicine, Inc. |
Nouvelles molecules de fusion et leurs utilisations
|
US8975279B2
(en)
|
2012-11-07 |
2015-03-10 |
Teva Pharmaceutical Industries, Ltd. |
Amine salts of laquinimod
|
EP3939614A1
(fr)
|
2013-01-18 |
2022-01-19 |
Foundation Medicine, Inc. |
Méthodes de traitement du cholangiocarcinome
|
US9777333B2
(en)
|
2013-04-05 |
2017-10-03 |
Life Technologies Corporation |
Gene fusion
|
GB201307577D0
(en)
|
2013-04-26 |
2013-06-12 |
Astex Therapeutics Ltd |
New compounds
|
WO2014193229A2
(fr)
|
2013-05-27 |
2014-12-04 |
Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis |
Nouvelles translocations dans le cancer du poumon
|
US20160129030A1
(en)
|
2013-06-14 |
2016-05-12 |
The Brigham And Women's Hospital, Inc. |
Treatment of mtor hyperactive related diseases and disorders
|
EP3007681A1
(fr)
|
2013-06-14 |
2016-04-20 |
Synthon B.V. |
Compositions pharmaceutiques stables et hydrosolubles comprenant du pémétrexed
|
EP3019628A4
(fr)
|
2013-07-12 |
2017-05-10 |
The Regents Of The University Of Michigan |
Fusions de gènes récurrentes dans le cancer
|
WO2015017607A2
(fr)
*
|
2013-08-02 |
2015-02-05 |
Cephalon, Inc. |
Méthodes de traitement de divers cancers utilisant un inhibiteur axl/cmet seul ou en association avec d'autres agents
|
US9221804B2
(en)
|
2013-10-15 |
2015-12-29 |
Janssen Pharmaceutica Nv |
Secondary alcohol quinolinyl modulators of RORγt
|
JP6752715B2
(ja)
|
2014-03-26 |
2020-09-09 |
アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited |
組合せ
|
JO3512B1
(ar)
|
2014-03-26 |
2020-07-05 |
Astex Therapeutics Ltd |
مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
|
CN106456648B
(zh)
|
2014-03-26 |
2021-11-02 |
阿斯特克斯治疗有限公司 |
Fgfr抑制剂和igf1r抑制剂的组合
|
LT3198033T
(lt)
|
2014-09-26 |
2022-05-10 |
Janssen Pharmaceutica Nv |
Fgfr mutantinių genų rinkinių panaudojimas identifikuojant vėžiu sergančius pacientus, kurie reaguos į gydymą fgfr inhibitoriumi
|
JOP20200201A1
(ar)
|
2015-02-10 |
2017-06-16 |
Astex Therapeutics Ltd |
تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
|
BR112017017700A2
(pt)
|
2015-02-19 |
2018-07-31 |
Bioclin Therapeutics Inc |
métodos, composições e kits para tratamento do câncer
|
US10478494B2
(en)
|
2015-04-03 |
2019-11-19 |
Astex Therapeutics Ltd |
FGFR/PD-1 combination therapy for the treatment of cancer
|
CN105030777B
(zh)
|
2015-07-14 |
2017-07-21 |
中国人民解放军第三军医大学第三附属医院 |
增强alk‑tki疗效、延缓其耐药的复合物及其制剂
|
CN105147687A
(zh)
|
2015-09-28 |
2015-12-16 |
青岛华之草医药科技有限公司 |
一种治疗白血病的药物达沙替尼组合物胶囊
|
JOP20190280A1
(ar)
|
2017-06-02 |
2019-12-02 |
Janssen Pharmaceutica Nv |
مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية
|